Eli Lilly-Backed Scribe Raises $128.7 Million in Upsized IPO
Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, raised $128.7 million in an upsized initial public offering priced at the top of its marketed range.
By Angel Adegbesan · Bloomberg
Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, raised $128.7 million in an upsized initial public offering priced at the top of its marketed range.